文献速递艾滋病与性传播感染结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

治疗前低丰度HIV-1耐药变异对HIV-1/TB共感染患者病毒学失败的影响

Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该病例对照研究纳入170例HIV-1/TB共感染成人,比较45例病毒学失败者与125例病毒抑制者的治疗前耐药变异。Sanger和MiSeq测序显示,≥20%阈值耐药总患病率为4.7%,仅低丰度耐药变异者病毒学失败风险无统计学显著升高。

要点

  • ≥20%阈值治疗前耐药与病毒学失败风险接近4倍升高,但无统计学显著性。
  • 包含≥2%低丰度变异后耐药患病率升至18.2%。
  • NGS提高耐药变异检出率,但低阈值未额外识别病毒学失败风险。

核心结论

  • 治疗前耐药变异和低丰度耐药变异增加NNRTI一线ART病毒学失败风险,但无统计学显著性。

研究设计与样本

  • 病例对照研究,纳入170例HIV-1/TB共感染成人,45例病例和125例对照。

主要发现

  • ≥20%阈值治疗前耐药总患病率为4.7%(8/170),病例组8.9%高于对照组3.2%(P=0.210)。
  • ≥20%阈值治疗前耐药者病毒学失败校正OR为3.7(95%CI 0.8-18.3,P=0.104)。
  • 仅低丰度耐药变异者病毒学失败校正OR为1.6(95%CI 0.6-4.3,P=0.398)。
  • 包含≥2%低丰度变异后,治疗前耐药患病率升至18.2%(31/170)。

临床怎么用

  • 对NNRTI一线ART的HIV-1/TB共感染患者,可考虑治疗前耐药检测,但低阈值NGS结果的临床决策价值尚不明确。

局限性

  • 研究未报告样本量计算和统计效能,部分比较置信区间宽且无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of pretreatment low-abundance HIV-1 drug-resistant variants (LA-DRVs) on virological failure (VF) among HIV-1/TB-co-infected individuals treated with NNRTI first-line ART. METHODS: We conducted a case-control study of 170 adults with HIV-1/TB co-infection. Cases had at least one viral load (VL) ≥1000 RNA copies/mL after ≥6 months on NNRTI-based ART, and controls had sustained VLs <1000 copies/mL. We sequenced plasma viruses by Sanger and MiSeq next-generation sequencing (NGS). We assessed drug resistance mutations (DRMs) using the Stanford drug resistance database, and analysed NGS data for DRMs at ≥20%, 10%, 5% and 2% thresholds. We assessed the effect of pretreatment drug resistance (PDR) on VF. RESULTS: We analysed sequences from 45 cases and 125 controls. Overall prevalence of PDR detected at a ≥20% threshold was 4.7% (8/170) and was higher in cases than in controls (8.9% versus 3.2%), P = 0.210. Participants with PDR at ≥20% had almost 4-fold higher odds of VF (adjusted OR 3.7, 95% CI 0.8-18.3) compared with those without, P = 0.104. PDR prevalence increased to 18.2% (31/170) when LA-DRVs at ≥2% were included. Participants with pretreatment LA-DRVs only had 1.6-fold higher odds of VF (adjusted OR 1.6, 95% CI 0.6-4.3) compared with those without, P = 0.398. CONCLUSIONS: Pretreatment DRMs and LA-DRVs increased the odds of developing VF on NNRTI-based ART, although without statistical significance. NGS increased detection of DRMs but provided no additional benefit in identifying participants at risk of VF at lower thresholds. More studies assessing mutation thresholds predictive of VF are required to inform use of NGS in treatment decisions.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chimukangara B, Giandhari J, Lessells R, et al. Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. J Antimicrob Chemother. 2020. PMID: 32772079. doi:10.1093/jac/dkaa343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。